Last updated on November 2017

A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD).


Brief description of study

A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD).

Detailed Study Description

The objective of the trial is to investigate the efficacy and safety of 150 mg bid nintedanib in patients with PF-ILD compared to placebo over 52 weeks (Part A).

The primary objective is to demonstrate a reduction in lung function decline, as measured by the annual rate of decline in FVC for nintedanib compared to placebo over 52 weeks.

Clinical Study Identifier: TX82328

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Kathleen McNulty, MHS, CCRC

The Lung Research Center
Chesterfield, MO USA
  Connect »